// App-Quantinova.ai

2510 : Cost-Effectiveness of Acalabrutinib Monotherapy Compared with Chlorambucil Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Researchers

Presenter

  • Talha Munir

Principal Investigators

  • Priyanka Gaitonde

  • Catherine Waweru

Medical Centers

  • St. James's University Hospital, Leeds, United Kingdom

  • AstraZeneca, Gaithersburg, MD

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • ACP-196

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Bendamustine

  • chlorambucil

  • Venetoclax

  • Ibrutinib

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved